Foundation for Neglected Disease Research
Foundation for Neglected Disease Research (FNDR) is a not-for-profit biotech R&D organization dedicated to discovering and developing novel therapeutics, diagnostics, and devices for diseases with a high socio-economic impact. Since 2014, FNDR has built a portfolio of therapeutics targeting infectious diseases such as tuberculosis, malaria, dengue, leishmania, bacterial and fungal infections, COVID-19, and RSV. The organization operates a state-of-the-art R&D center in Bengaluru, India, with biosafety level laboratories and a team of over 20 scientists. FNDR collaborates globally, conducts preclinical and clinical research, and aims to contribute to global health goals by developing new treatments and diagnostics for neglected diseases.
Industries
Nr. of Employees
small (1-50)
Foundation for Neglected Disease Research
Plot No. 20A, KIADB Industrial Area, Veerapura, Doddaballapur, Bangalore - 561203, Karnataka, India
Patents
Microparticle formulation for pulmonary drug delivery of anti infective molecule for treatment of infectious diseases
US-8697653-B2
View Details
Microparticle formulation for pulmonary drug delivery of anti infective molecule for treatment of infectious diseases
US-8697653-B2
View DetailsProducts
DprE1 inhibitor (clinical candidate progressed to Phase 2A)
A small-molecule DprE1-targeting anti-tubercular compound that progressed through Phase 1 and Phase 2A clinical evaluation, showing dose-dependent bactericidal activity in early bactericidal activity studies.
Oxazolidinone series for non-tuberculous mycobacteria
An oxazolidinone-class small molecule series with efficacy against non-tuberculous mycobacteria and an improved safety profile, in preclinical development.
Oral formulation of amphotericin B (antifungal candidate)
Oral formulation development of a broad-spectrum antifungal agent intended to address serious fungal infections; program listed in organizational pipeline.
Diagnostic: blood-based bacterial vs viral differentiation
A blood-based diagnostic under development for rapid differentiation between bacterial and viral infections to guide antibiotic prescriptions; preclinical validation completed.
RT-LAMP nucleic acid assay for lymphatic filariasis (proof of concept)
Total nucleic acid reverse-transcription loop-mediated isothermal amplification (RT-LAMP) based detection approach developed for lymphatic filariasis; proof-of-concept studies funded.
Novel compound series for dengue and Zika (hit-to-lead)
Small-molecule series active against multiple dengue serotypes and Zika virus, currently at hit-to-lead stage in collaboration with academic partners.
DprE1 inhibitor (clinical candidate progressed to Phase 2A)
A small-molecule DprE1-targeting anti-tubercular compound that progressed through Phase 1 and Phase 2A clinical evaluation, showing dose-dependent bactericidal activity in early bactericidal activity studies.
Oxazolidinone series for non-tuberculous mycobacteria
An oxazolidinone-class small molecule series with efficacy against non-tuberculous mycobacteria and an improved safety profile, in preclinical development.
Oral formulation of amphotericin B (antifungal candidate)
Oral formulation development of a broad-spectrum antifungal agent intended to address serious fungal infections; program listed in organizational pipeline.
Diagnostic: blood-based bacterial vs viral differentiation
A blood-based diagnostic under development for rapid differentiation between bacterial and viral infections to guide antibiotic prescriptions; preclinical validation completed.
RT-LAMP nucleic acid assay for lymphatic filariasis (proof of concept)
Total nucleic acid reverse-transcription loop-mediated isothermal amplification (RT-LAMP) based detection approach developed for lymphatic filariasis; proof-of-concept studies funded.
Novel compound series for dengue and Zika (hit-to-lead)
Small-molecule series active against multiple dengue serotypes and Zika virus, currently at hit-to-lead stage in collaboration with academic partners.
Services
On-site provision of preclinical testing services for BSL-2 and BSL-3 pathogens, including therapeutics, vaccine and virucidal efficacy studies in cell-based and animal models.
Development and preclinical validation of diagnostic assays including biomarker-based tests to differentiate bacterial vs viral infections and nucleic-acid amplification assays.
On-site provision of preclinical testing services for BSL-2 and BSL-3 pathogens, including therapeutics, vaccine and virucidal efficacy studies in cell-based and animal models.
Development and preclinical validation of diagnostic assays including biomarker-based tests to differentiate bacterial vs viral infections and nucleic-acid amplification assays.
Expertise Areas
- Infectious disease drug discovery
- Tuberculosis and non-tuberculous mycobacterial therapeutics
- Antibacterial drug development and antimicrobial resistance (AMR)
- Antifungal therapeutics development
Key Technologies
- Biosafety Level 3 laboratory infrastructure
- Flow cytometry (FACS)
- LC-MS/MS pharmacokinetic assays
- RT-PCR
News & Updates
FNDR announced successful completion of Phase 2A trial of TBA-7371, a DprE1 inhibitor for TB, showing significant bactericidal activity.
FNDR collaborates on an international project to optimize new chemical structures effective against Gram-negative bacteria.
Funding for preclinical development of a therapeutic for non-tuberculous mycobacterial infections in cystic fibrosis patients.
Funding to develop a device for antibiotic depletion from hospital effluents.
Partnership to enable SARS-CoV-2 research for academia and industry.
Received approval from Indian authorities to conduct research with SARS-CoV-2 in BSL-3 facilities.
FNDR announced successful completion of Phase 2A trial of TBA-7371, a DprE1 inhibitor for TB, showing significant bactericidal activity.
FNDR collaborates on an international project to optimize new chemical structures effective against Gram-negative bacteria.
Funding for preclinical development of a therapeutic for non-tuberculous mycobacterial infections in cystic fibrosis patients.
Funding to develop a device for antibiotic depletion from hospital effluents.
Partnership to enable SARS-CoV-2 research for academia and industry.
Received approval from Indian authorities to conduct research with SARS-CoV-2 in BSL-3 facilities.